Clinical trials: Autosomal Dominant Polycystic Kidney
Autosomal Dominant Polycystic Kidney
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease
Patients affected by Autosomal Dominant Polycystic Kidney Disease (ADPKD) need a safe and effective long-term treatment regimen. Unfortunately, there are still no disease-specific treatment for ADPKD approved in the US.
- Trial name
- NCT03102632
- Testing
- High Water Intake
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The Rogosin Institute
Polycystic Kidney, Autosomal Dominant
Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
This study's purpose is to evaluate the long-term safety of open-label tolvaptan regimens to determine the maximally-tolerated dose and acquire pilot efficacy data in patients with autosomal dominant polycystic kidney disease…
- Trial name
- TEMPO 2:4 (NCT00413777)
- Testing
- Tolvaptan
- Where
- 11 sites in United States
- Volunteers
- 46 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Polyuria, Autosomal Dominant Polycystic Kidney
Dietary Intervention in ADPKD on Tolvaptan
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder. Tolvaptan has been approved in Canada as a treatment for ADPKD.
- Trial name
- DIAT (NCT03858439)
- Testing
- Dietary
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- McMaster University
Autosomal Dominant Polycystic Kidney, Obesity
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can…
- Trial name
- NCT06582875
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Colorado, Denver
Autosomal Dominant Polycystic Kidney Disease
Analysis of Clinical and Molecular Genetic Data Influencing the Evolution and Response to Therapy of ADPKD Patients (Autosomal Dominant Polycystic Kidney Disease)
Genkyst is a regional cohort involving up to nephrologists working in private and public nephrology centers in the West of France.
- Trial name
- GENKYST (NCT02887729)
- Where
- 26 sites in France
- Volunteers
- 4,000 people
- Sponsor
- University Hospital, Brest
Autosomal Dominant Polycystic Kidney
Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease
Investigator initiated controlled multi-centre trial in a Prospective, Randomised, Open, Blinded Endpoint (PROBE) design. Patients will be randomised in a 1:1 ratio either to treatment with tolvaptan for six weeks followed by six…
- Trial name
- PoCKET (NCT03596957)
- Testing
- Tolvaptan
- Where
- 6 sites in Denmark
- Volunteers
- 90 people
- Sponsor
- Lisbet Brandi
Autosomal Dominant Polycystic Kidney Disease
The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
The investigators multicenter randomized open-labelled study will investigate the efficacy of an everolimus based immunosuppression in reducing total native kidney volume in kidney recipients with autosomal dominant polycystic…
- Trial name
- EVERKYSTE (NCT02134899)
- Testing
- Everolimus, Calcineurin inhibitors maintenance
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
To collect characteristics of patients with ADPKD across a broad population, over time to better understand disease progression (signs, symptoms and outcomes).
- Trial name
- OVERTURE (NCT01430494)
- Where
- 266 sites in United States, Argentina and 18 more
- Volunteers
- 3,409 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
ADPKD, Pain
Somatosensory Phenotyping of ADPKD
Over 60% of patients with ADPKD suffer from pain, mostly in the abdomen, flank and back, often leading to the diagnosis. It is challenging to manage and cure the pain; approximately 39% of patients are not satisfied with their…
- Trial name
- NCT06970028
- Testing
- Quantitative Sensory Testing, Questionnaires regarding pain and quality of life
- Where
- Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Triptolide was shown in experimental studies to inhibit the cyst formation and growth in ADPKD models, while triptolide-containing formulation was revealed to potentially slow the disease progression in several proteinuric ADPKD…
- Trial name
- NCT02115659
- Testing
- Triptolide-Containing Formulation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Changzheng Hospital
Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
Multicenter trial on the effect of the GnRH analogue leuprorelin on the growth of total liver volume in pre-menopausal women with very severe polycystic liver disease who, despite available therapy, experience growth and are…
- Trial name
- AGAINST-PLD (NCT05478083)
- Testing
- Leuprorelin
- Where
- 2 sites in Netherlands
- Volunteers
- 36 people
- Sponsor
- University Medical Center Groningen
Polycystic Kidney Disease
Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
Funding Source - FDA OOPD Pioglitazone is currently used in clinical practice to treat diabetes and this study will examine the potential use of a low dose of the same drug for the treatment of polycystic kidney disease.
- Trial name
- PIOPKD (NCT02697617)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Indiana University
ADPKD
Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?
The investigators are running a study to see if a special drink, called a "ketone ester", can help people with a type of kidney disease named "Autosomal Dominant Polycystic Kidney Disease" or ADPKD for short.
- Trial name
- ADKETONE (NCT06100133)
- Testing
- Ketone ester
- Volunteers
- 20 people
- Sponsor
- Universitair Ziekenhuis Brussel
Polycystic Kidney, Type 1 Autosomal Dominant Disease, Polycystic Kidney, Type 2 Autosomal Dominant Disease
Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease
Sirolimus (SIR) has lead to a reduction of overall kidney size, a decrease in cyst density and general tubular cell proliferation in animal models, and to a reduction of the increase in creatinine and blood urea nitrogen by 34…
- Trial name
- RAP (NCT02055079)
- Testing
- Sirolimus
- Where
- Austria
- Volunteers
- 68 people
- Sponsor
- Medical University of Vienna
Autosomal Dominant Polycystic Kidney Disease
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]
ADPKD patients who were enrolled in Study 156-05-002 will receive repeated oral administration of OPC-41061 at doses of 15 mg twice daily (morning and evening).
- Trial name
- NCT01022424
- Testing
- OPC-41061
- Where
- Japan
- Volunteers
- 13 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Polycystic Kidney Disease, Adult, ADPKD
Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
This is a Phase 3, open-label, repeat-dose study designed to assess liver safety, non-liver safety, and efficacy of lixivaptan in participants who previously experienced liver chemistry test abnormalities while treated with…
- Trial name
- ALERT (NCT04152837)
- Testing
- Lixivaptan
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Palladio Biosciences
Polycystic Kidney, Autosomal Dominant
A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
The primary objective of this study Phase 1b was to determine the safety, plasma pharmacokinetics, and maximum tolerated dose (MTD) of tesevatinib when administered to participants with autosomal dominant polycystic kidney…
- Trial name
- NCT01559363
- Testing
- Tesevatinib
- Where
- 11 sites in United States
- Volunteers
- 69 people
- Sponsor
- Kadmon, a Sanofi Company
Kidney, Polycystic, Autosomal Dominant
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain Study
We will enroll 20 patients to evaluate the effectiveness of a new operation known as videothoracoscopic splanchnicectomy (VSPL) for management of chronic kidney pain.
- Trial name
- NCT00571909
- Testing
- video thorascopic splanchnicectomy (VSPL)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Autosomal Dominant Polycystic Kidney
Outcome of ADPKD With Octreotide LAR
In this observational, retrospective study we will primarily aim at evaluating the independent role of baseline clinical and laboratory parameters, including TKV, in the prediction of long term chronic GFR decline and other…
- Trial name
- ADPKD648 (NCT06193616)
- Testing
- Octreotide
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Autosomal Dominant Polycystic Kidney Disease
ADPKD and Peritoneal Dialysis: How Anticipate Peritoneal Pressure?
Autosomal dominant polycystic kidney disease (ADPKD) is first genetic kidney disease and fourth etiology of end stage renal disease in the world. Peritoneal dialysis is underuse in this population.
- Trial name
- PDP-ADPKD (NCT03970018)
- Testing
- Intra-peritoneal pressure
- Where
- France
- Volunteers
- 210 people
- Sponsor
- CHU de Reims